TABLE 1.
Dalbavancin pharmacokinetic parameters following administration of a single 30-min intravenous infusion to healthy male and female subjectsa
| Doseb (mg) | Tmax | Cmax (mg/liter) | AUC (mg · h/liter) | CL (liters/h) | Vss (liters) | t1/2 (h) |
|---|---|---|---|---|---|---|
| 140 | 0.5 (0.5-1.0) | 40.1 (37.9-41.1) | 3,234 (3,174-3,344) | 0.0433 (0.0419-0.0441) | 10.9 (10.7-11.1) | 188 (186-193) |
| 220 | 0.5 (0.5-0.5) | 71.4 (48.4-76.1) | 5,004 (4,370-5,490) | 0.044 (0.0401-0.0503) | 11.0 (10.1-12.7) | 186 (172-207) |
| 350 | 0.5 (0.5-0.5) | 96.3 (89.1-103) | 8,104 (6,904-9,276) | 0.0432 (0.0377-0.0507) | 11.0 (8.2-12.8) | 188 (162-192) |
| 500 | 0.5 (0.5-0.5) | 133 (131-195) | 11,393 (11,200-14,758) | 0.0439 (0.0339-0.0446) | 9.01 (7.19-9.54) | 162 (154-163) |
| 630 | 1.0 (0.5-1.0) | 170 (143-256) | 12,616 (12,257-19,400) | 0.0499 (0.0325-0.0514) | 11.3 (6.96-13.2) | 168 (158-190) |
| 840 | 0.5 (0.5-0.5) | 239 (235-256) | 21,949 (21,253-23,474) | 0.0383 (0.0358-0.0395) | 7.85 (7.15-8.24) | 149 (148-158) |
| 1,120 | 0.5 (0.5-0.5) | 312 (292-371) | 27,103 (22,967-27,299) | 0.0413 (0.041-0.0488) | 7.93 (7.84-9.70) | 149 (145-153) |
a
The values shown are medians (ranges are in parentheses).
b
There were three subjects in each group.